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Abstract 
The effectiveness of the antimicrobial peptide maximin-4, the ultrashort peptide H-
Orn-Orn-Trp-Trp-NH2 and the lipopeptide C12-Orn-Orn-Trp-Trp-NH2 in preventing 
adherence of pathogens to a candidate biomaterial were tested utilising both matrix 
and immersion loaded poly(2-hydroxyethyl methacrylate) (poly(HEMA)) hydrogels.  
Anti-adherent properties correlated to both the concentration released and the relative 
antimicrobial concentrations of each compound against Staphylococcus epidermidis 
ATCC 35984, at each time point.  Immersion loaded samples containing C12-Orn-
Orn-Trp-Trp-NH2 exhibited the lowest adherence profile for all peptides studied over 
1, 4 and 24 hours.  The results outlined in the following paper show that antimicrobial 
peptides have the potential to serve as an important weapon against biomaterial 
associated infections.   
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1  Introduction 
In the UK medical device related infections are estimated to cost somewhere in the 
range of £7-11 million per year.1  This can be attributed, in part, to both the increasing 
emergence of multidrug resistant pathogenic microorganisms and an increasing 
demand for implantable therapeutics or biomaterials to support normal physiological 
function in an ageing population.2  Implantable medical devices provide an optimum 
environment for the growth of microorganisms including opportunistic pathogens 
derived from the normal microflora of the body.3  In these scenarios bacteria exhibit a 
sessile biofilm phenotype, composed of aggregated microcolonies of cells surrounded 
by a protective extracellular polymeric matrix.4  The microbial colonisation of the 
surface and the formation of a hydrophobic, polysaccharide matrix provides 
microorganisms with a greater degree of protection against environmental stresses 
allowing biofilms to resist flow, increase utilisation of nutrients and energy, and 
increase antimicrobial resistance/tolerance.5 
Whilst efforts have intensified to find novel alternatives to existing treatment 
strategies, successes have been limited and have failed to keep with the rapid 
emergence of resistance among pathogenic microorganisms.6  Therapeutic regimens 
tend only to act efficiently on multiplying bacteria by interference of cellular 
processes, leaving a reservoir of non-multiplying bacteria.7  As a result, their potential 
future use as chemotherapeutic agents is limited as eradication of the biofilm matrix 
and persister cells does not occur at the similarly low concentrations for planktonic 
kill.8  These non-multiplying dormant cells are often responsible for the failure of 
standard antimicrobial regimens and spread of resistant strains due to their low 
metabolism and reduced uptake of antibiotics that act on bacterial metabolic 
pathways.7  These persister cells are responsible for 60% of all clinical bacterial 
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infection9 and are linked to the reoccurrence of infections previously thought to be 
eradicated.10 
One promising area of antimicrobial drug research is that of cationic 
antimicrobial peptides.  Antimicrobial peptides in nature serve as important defensive 
weapons in the innate immune system of both prokaryotic and eukaryotic organisms 
against a broad spectrum of bacterial and fungal pathogens.11  Antimicrobial peptides 
exert their microbicidal effect via disruption of the microbial cell membrane together 
with intracellular action.12  The multiple modes of action utilised by antimicrobial 
peptides reduces the ability of microorganisms to develop resistance, with cidal 
activity also shown against bacteria resistant to standard antibiotics.13  Research 
conducted by Lai et al showed that the species of frog Bombina maxima produced a 
group of cationic antimicrobial peptides called maximins that demonstrated MIC 
values in the µg/mL range against a broad spectrum of microbial pathogens including 
Staphylococcus aureus, Escherichia coli, Bacillus dysenteriae, Klebsiella pneumoniae 
and Candida albicans.14  Maximin-4 was the most potent peptide tested having the 
lowest minimum inhibitory concentration value of 2.7µg/mL against Staphylococcus 
aureus.  Maximin-4 consists of twenty seven amino acids 
(GIGGVLLSAGKAALKGLAKVLAEKYAN) and has the potential to be synthesised 
via facile solid phase peptide synthesis.  The initial target of these cationic 
antimicrobial peptides has been proven to be the negatively charged membrane of 
bacteria.15   
Structure activity relationship analyses have shown the activity and selectivity 
of cationic antimicrobial peptides to be governed by the overall hydrophobic:charge 
ratio of the primary amino acid sequence.16  Further work has allowed the 
identification of a structural pharmacophore (two units of bulk and two cationic 
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charges) that acts as the minimum motif for antimicrobial activity.17  Based on this, 
Bisht and colleagues produced a series of amino terminal modified peptides 
containing two ornithine (Orn) (providing charge) and two tryptophan residues (Trp) 
(providing lipophilicity and bulk), with significantly reduced MIC values for amino 
terminal peptides in comparison to C-terminal carboxylic acids.18   The obvious 
advantage to the use of an ultrashort antimicrobial peptide is the large reduction in 
cost and ease of synthesis relative to synthetic variants of naturally occurring 
antimicrobial peptides.  The attachment of an acyl chain to an active or inert ultrashort 
cationic peptide also potentially leads to an increased action against microorganisms 
in a similar way to native cationic antimicrobials.19  
Previous work by in our laboratory showed the attachment of an N-terminal 
C12 (dodecyl) acyl substituent to the H-Orn-Orn-Trp-Trp-NH2 tetrapeptide standard 
produced an ultrashort lipopeptide with increased antimicrobial potency against 
established biofilm forms of Gram-positive staphylococci attributed to medical device 
related infections.20  A concentration as low as 15.63µg/mL of C12-Orn-Orn-Trp-Trp-
NH2 was shown to completely eradicate mature 24 hour biofilms of Staphylococcus 
epidermidis ATCC 35984, with antibiofilm activity measured by determination of the 
minimum biofilm eradication concentrations (MBEC) utilising the Calgary biofilm 
device and MBEC Assay for Physiology & Genetics.21   
In this report we describe the synthesis, drug release characteristics of a range 
of novel antimicrobial peptide matrix and immersion loaded hydrogel polymers based 
on the monomer 2-hydroxyethyl methacrylate (HEMA), widely used in the 
manufacture of medical device coatings.  Due to the promising antimicrobial 
properties displayed by the antimicrobial peptide maximin-4 and the lipopeptide C12-
Orn-Orn-Trp-Trp-NH2 described by our group, we examine the use of these 
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compounds incorporated in hydrogel matrices for the prevention of medical device 
infection, focusing on prevention of adherence by Staphylococcus epidermidis one of 
the main causative pathogens of device associated infections.  Staphylococcus 
epidermidis was selected as this microorganism is representative of all Gram-positive 
pathogens in that it is responsible for a large proportion of medical device related 
infections due, in part, to its ability to form a biofilm resistant to standard 
antimicrobial regimens.22  Vancomycin was selected as a comparative control for 
standard antimicrobials due to its use clinically, particularly with regard to 
staphylococcal infections.23 
 
2  Experimental  
2.1  Materials 
Rink amide 4-(2’,4’-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-
MHBA (MBHA) resin, all 9-fluorenylmethoxy carbonyl (Fmoc) L-amino acids 
(Fmoc-Orn(Boc)-OH and Fmoc-Trp(Boc)-OH) and 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), N-Methyl-2-pyrrolidone 
(NMP), piperidine, trifluoroacetic acid, triisopropylsilane and thioanisole were 
obtained from Merck Chemicals Ltd. (Nottingham, UK).  Fatty acid; dodecanoic 
(lauric) acid, phosphate buffer saline (PBS) tablets and vancomycin (as hydrochloride 
hydrate) were obtained from Sigma-Aldrich (Dorset, UK).  All other 
reagents/solvents were peptide synthesis grade.  HEMA, 1% ethylene glycol 
dimethacrylate (EGDMA) and 0.4% benzoyl peroxide were obtained from Sigma-
Aldrich (Dorset, UK). 
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2.2  Peptide Synthesis 
All Peptides were synthesised using standard Fmoc solid phase protocols on Rink 
Amide MHBA resin, using a CEM Liberty (Buckingham, UK) microwave enhanced 
automated peptide synthesiser at 1 millimolar scale as previously reported.20  
Removal of the Fmoc grouping from the protected resin and amino acids 
(deprotection) occurred in 20% piperidine in Dimethylformamide.  Peptide 
elongation/coupling was performed using HBTU/NMP and a three-fold molar excess 
of each Fmoc-protected amino acid or free hydrocarbon containing acid derivative.  
Coupling occurred at standard (microwave enhanced) amino acid coupling conditions 
(18 Watt, 75ºC, 300 seconds) and was employed for all syntheses.  Automated 
synthesis yielded synthesised peptide attached to the Rink amide MHBA resin.  All 
synthesised peptides were cleaved from the resin in a round bottom flask using 95% 
Trifluoroacetic acid, 2.5% triisopropylsilane and 2.5% thioanisole (2 hours, room 
temperature and pressure).  The synthesised peptide, present in the solvent phase, was 
separated from the resin by vacuum filtration under reduced pressure using a Büchner 
funnel and flask.  Excess solvent was removed under reduced pressure via rotary 
evaporation.  The peptide remaining was precipitated using cold diethyl ether, 
lyophilised and stored at -20ºC until required for further analysis.  Peptide purity was 
analysed by Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) 
using a Gemini C18, 250 mm x 4.6 mm column (Phenomonex, UK), a 2-60% 
acetonitrile gradient [30min] in 0.05% trifluoroacetic acid-water at a flow rate of 1 
mL/min.  All peptides/lipopeptides were found to have >90% purity.  
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2.3  Strains & Growth Conditions 
Staphylococcus epidermidis ATCC 35984 was stored at -80 C in Microbank vials 
(Pro-Lab Diagnostics, Cheshire, UK) and subcultured in Müller Hinton Broth (MHB) 
before testing. 
 
2.4  Matrix Loaded Poly(HEMA) Hydrogel Synthesis 
Matrix loaded poly(HEMA) polymers were synthesised by free radical solution 
polymerization of the monomer, HEMA with chemical initiation in a similar method 
to that employed by Parsons et al.24  1% EGDMA was used as a crosslinker with 
0.4% benzoyl peroxide used as a radical initiator.  H-Orn-Orn-Trp-Trp-NH2, C12-Orn-
Orn-Trp-Trp-NH2, maximin-4 and vancomycin were added after free radical initiation 
at 0.5%, 1% and 5% ratios relative to total hydrogel content.  Dissolution was 
achieved by stirring at 1000rpm for 2 hours at room temperature (to ensure 
homogeneity, with visual conformation) and the mixture was injected into a mould 
comprising of two vertical glass plates lined with release liner (3M), separated by 
silicon tubing of diameter 3mm and cured in a Gallenkamp box oven at 90ºC for 2 
hours.  A non-drug containing poly(HEMA) hydrogel was produced to provide 
positive controls.  Each antimicrobial was proven to be thermally stable under the 
conditions employed for hydrogel synthesis (90ºC for 2 hours).  Antimicrobial 
activity was linked to structural stability in a similar manner to the theory employed 
by Lappe et al.25  Values for minimum inhibitory (MICs) and minimum bactericidal 
concentrations (MBCs) against Staphylococcus epidermidis ATCC 35984, utilising 
National Committee for Clinical Laboratory Standards (NCCLS) guidelines in a 
method similar to that described by Andrews,26 were shown to be the same both 
before and after heat treatment. 
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2.5 Immersion Loaded Poly(HEMA) Hydrogel Synthesis 
Immersion loaded hydrogels were produced by swelling of non drug containing 
poly(HEMA) hydrogels in drug containing solutions.27  Non-drug containing 
poly(HEMA) hydrogels were synthesised as previously for the poly(HEMA) control 
for matrix loaded hydrogels.  After curing hydrogels were washed in distilled water 
(replaced with fresh solution each day) at room temperature for 14 days to ensure 
removal of reaction products/unreacted monomers.24  Washed hydrogels were stored 
in distilled water until ready to be cut for analysis using a sterile size number 8 cork 
borer (1cm diameter).  Drug containing immersion solutions (20mg/mL, 10mg/mL 
and 5mg/mL) were formed by addition of H-Orn-Orn-Trp-Trp-NH2, C12-Orn-Orn-
Trp-Trp-NH2, maximin-4 and vancomycin to 10mLs sterile PBS of pH 7.4 (pH was 
tested using a calibrated Hanna pH 209 pH meter) in sterile McCartney jars.  Circular 
samples of poly(HEMA) hydrogels (1cm diameter, 3mm length) were dried in a 
Gallenkamp box oven (60ºC for 24 hours) to ensure that residual moisture was 
removed and a constant weight achieved (weighed at 0, 23 and 24 hour time points).  
These dried poly(HEMA) samples were immersed in drug solution for 24 hours at 
room temperature before release and adherence analysis.   
 
2.6 Release Properties of Antimicrobials via Matrix and Immersion Loaded 
Poly(HEMA) Hydrogels   
Samples of 0.5%, 1%, 5% matrix loaded and 20mg/mL, 10mg/mL, 5mg/mL 
immersion loaded hydrogels of H-Orn-Orn-Trp-Trp-NH2, C12-Orn-Orn-Trp-Trp-NH2, 
maximin-4 and vancomycin were manufactured as described in Section 2.4 and 2.5.  
Each sample was placed in a preheated 10.5mL vial containing 10mLs of PBS (pH 
7.4) at 37ºC.  Sample vials were then transferred to a Grant SS40-D shaking bath for a 
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total of 2 weeks at 37ºC and 100 strokes per minute.  Five replicates were studied at 
each drug concentration.  Each hydrogel sample was removed at 0, 0.25, 0.5, 0.75, 1, 
1.5, 2, 4, 6, 18, 24, 78, 168, 192, 216, 264, and 336 hours and placed in fresh 
preheated 10.5mL vial containing 10mLs of PBS (pH 7.4) at 37ºC.  PBS solution with 
released drug was then analysed for concentration of drug via UV-visible 
spectroscopy at a defined peak wavelength (nm) and a fresh calibration curve utilising 
a Varian Cary 50 UV-visible spectrophotometer, a quartz cuvette and following the 
Beer-Lambert law.  All release studies were carried out under sink conditions, that is, 
in a volume of dissolution medium that is at least 5 to 10 times the saturation 
volume.28  Modelling of drug release profiles was performed using a simple Power 
Law based equation derived by Ritger and Peppas.29  Modelling of release data in this 
way can allow for the calculation of the total quantity of drug eluted over a particular 
time period.  In order to obtain the most accurate data from experimental results, 
Power Law modelling is typically applied to the first 60% of total drug release 
curves.30 
nt Kt
M
M  	
 
Where Mt and M ∞ are the absolute cumulative amount of drug released at time t and 
infinite time respectively.  K is a constant that incorporates both the structural and 
geometric character of the device, whilst the release exponent n indicates the 
mechanism of drug release.   
The Power law was used to model the drug release mechanism via 
determination of the release exponent (n).  When the log10 fraction of total drug 
released is plotted against the log10 time, for values up to 60% of total drug released, 
the release exponent (n) is equivalent to the gradient of this graph.31  The above 
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equation, representing a linear fit model, can be modified to a logarithmic function 
according to Wang et al.32  
tnK
M
Mreleased t loglog)log()log(%   
To characterise different release mechanisms Peppas et al used this n value, with the 
values obtained with samples in the shape of flat disks (radius>thickness).30  This 
model is used to analyse the release of polymeric dosage forms, when the release 
mechanism is undefined or more than one type of release phenomena could be 
involved.33 
 
2.7 Anti-adherent Properties of Matrix and Immersion Loaded Poly(HEMA) 
Hydrogels against Staphylococcus epidermidis ATCC 35984  
The anti-adherent properties of synthesised poly(HEMA) hydrogels were evaluated 
by modification of a method used by Jones and colleagues.34, 35  Inocula of the biofilm 
forming pathogen Staphylococcus epidermidis ATCC 35984 were incubated 
overnight in the orbital incubator for approximately 18-24 hours so that the organism 
was in the late stationary growth phase.  Cultures were centrifuged in sterile 
centrifuge tubes at 3000rpm for 15min using a Sigma 3-16P centrifuge.  The 
supernatant liquid was poured into disinfectant and the pellet resuspended in PBS (pH 
7.4) to obtain an optical density of 0.9 (540nm) using a WPA colourwave CO7500 
colourimeter.  This gave give an approximate inoculum size of 4.5 x108 colony 
forming units per mL (CFU/mL) as verified by a Miles and Misra viable count.  The 
hydrogels, manufactured disks cut with a size number 8 cork borer (1cm diameter) as 
per release method, were placed on sterile hypodermic syringe needles, five samples 
per needle.  Positive controls provided for matrix and immersion loaded drugs by non 
drug containing poly(HEMA) hydrogels.  20mLs of the inoculum was added to a 
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sterile McCartney bottle containing each poly(HEMA) samples (one McCartney 
corresponding to each time point and sample concentration).  This volume was 
sufficient to completely cover the materials.  These were placed in an incubator 
shaker and removed at 1, 4 and 24 hour time intervals.  Using sterile forceps each 
needle holding the five disks was removed and placed in a fresh sterile McCartney 
containing approximately 20mLs of quarter strength ringers solution (QSRS).  Shaken 
vigorously for 30 seconds, to ensure non-adhered organisms/materials were removed, 
this procedure was repeated twice more.  To remove adhered organisms each 
hydrogel disc was placed in a separate sterile test tube containing 10mLs QSRS and 
sonicated for 10 minutes using a Branson 3510 sonic bath and vortexed for 30 
seconds at 42KHz (± 6%).  It has been shown previously that sonication, at this level, 
does not affect either microbial viability or morphology.36  The QSRS containing 
resuspended bacteria was decanted into another sterile test tube so as to prevent 
readherence.  A Miles and Misra viable count was performed to determine the number 
of organisms adhered via serial dilutions with culturing on Müeller-Hinton agar 
plates.  These were incubated overnight and then counted (CFU/disc) before 
calculation of the percentage adhered of the number of colony forming units per disc 
via comparison to the positive control. 
 
2.8   Statistical Analysis 
Adherence characteristics of H-Orn-Orn-Trp-Trp-NH2, C12-Orn-Orn-Trp-Trp-NH2, 
maximin-4 and vancomycin matrix loaded and immersion loaded, 1% EGDMA 
crosslinked, poly(HEMA) hydrogels were all compared using a one way ANOVA, 
with a Tukey-Kramer multiple comparisons test used to identify individual 
differences.  In all cases a probability of p ≤ 0.05 denoted significance. 
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3  Results and discussion 
3.1  Release Properties of Antimicrobials via Matrix and Immersion Loaded 
Poly(HEMA) Hydrogels   
EGDMA (1%) crosslinked poly(HEMA) hydrogels were utilised as a potential 
medical device coating and antimicrobial carrier due to its ability to release entrapped 
drug in aqueous solution and their excellent biocompatibility.37  The release of drug 
and swelling characteristics can be altered via changing of the crosslinking density.38  
In this study the crosslinking density was kept constant at 1% using EGDMA in order 
to determine the effect of antimicrobial peptide concentration on release and 
adherence kinetics.24  Poly(HEMA) hydrogels consist of separate regions containing 
water and polymer chains, with the water containing regions providing pores for the 
release of drug molecules.39  The monomer of HEMA possesses anionic character 
which is also present in its polymeric form.  The use of anionically charged hydrogels 
allow strong electrostatic interactions to develop with cationic molecules such as H-
Orn-Orn-Trp-Trp-NH2, C12-Orn-Orn-Trp-Trp-NH2 and  maximin-4 for both matrix 
and immersion loaded hydrogels, as similarly shown for cationic compounds such as 
benzalkonium and cetrimide in Poly(HEMA) based contact lens.40, 41  This property 
enables the retention of these cationic compounds with the possibility of favourable 
sustained release kinetics over many days/weeks. 
Figure 1 is provided as an example of the cumulative percentage drug release 
of the antimicrobial peptides, specifically C12-Orn-Orn-Trp-Trp-NH2, from a 0.5%, 
1% and 5% matrix loaded poly(HEMA) hydrogel over a period of 2 weeks.  Both H-
Orn-Orn-Trp-Trp-NH2 and maximin-4 show similar release patterns to matrix and 
immersion loaded C12-Orn-Orn-Trp-Trp-NH2 hydrogels.  5% matrix loaded 
poly(HEMA) showed a release of 2420µg of peptide over 2 weeks (36.9% compared 
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to theoretical).  1% (60.0% of theoretical released in 2 weeks) and 0.5% (94.6% of 
theoretical released in 2 weeks) C12-Orn-Orn-Trp-Trp-NH2 matrix loaded 
poly(HEMA) show a similar pattern of increasing percentage drug release relative to 
theoretical concentration when the percentage drug within the hydrogel decreases.  
The lipophilicity:charge balance of C12-Orn-Orn-Trp-Trp-NH2 may have allowed it to 
be retained within the polymer matrix at higher concentrations (5%) but still be 
sufficiently soluble to release a larger percentage of matrix loaded compound over 2 
weeks.   
Immersion loaded hydrogels, shown by the example of 20, 10 and 5mg/mL 
immersion loaded C12-Orn-Orn-Trp-Trp-NH2 poly(HEMA) hydrogels in Figure 2, did 
not retain any drug after the 2 week release assay, all compounds were released within 
78 hours.  These results are indicative of reduced interactions of the drug solutions 
with the poly(HEMA) matrix compared with matrix loaded hydrogels.  For example, 
the theoretical mass of C12-Orn-Orn-Trp-Trp-NH2 present in a poly(HEMA) hydrogel 
sample after 24 hour immersion in a 10mL solution of 20µg/mL (maximum 
concentration evaluated) was 12000µg.  After 78 hours, 10900µg of C12-Orn-Orn-
Trp-Trp-NH2 (90.8%) was released. 
Analysis of the cumulative percentage of experimental drug released from 
poly(HEMA) hydrogels over 2 weeks showed for matrix loaded hydrogels that up to 
70% of the cumulative drug released over 2 weeks was released in the first 24 hours 
irrespective of percentage drug loading.  In vitro results for immersion loaded 
poly(HEMA) hydrogels show 100% of all compounds were released within 78 hour 
contact with PBS, with almost 70% of the cumulative drug released over 2 weeks 
released in 4 hours.   
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The ideal scenario, as provided in the first 3 days by both matrix and 
immersion loaded poly(HEMA) hydrogels, is that the release of the antimicrobial 
compound should be high initially (also known as burst release) when the risk of 
infection and microbial adherence is at its greatest, followed by a longer period of 
controlled drug release at microbicidal levels.42  A longer period of controlled 
antimicrobial release is absent in immersion loaded hydrogels and they are therefore 
at increased risk to the development of infection after 78 hours.  Release of polymer 
could initially be reduced and delayed by increasing the degree of crosslinking.43 
Determination of the release exponent (n) allowed information to be obtained 
about the physical mechanism of drug release from both matrix and immersion loaded 
poly(HEMA), 1% crosslinked hydrogels.  The diffusional exponent, n, is dependent 
on the geometry of the device as well as the physical mechanism for release and is 
thus varied between slab and cylindrical polymers.44  All matrix and immersion 
loaded samples had a value of n greater than 0.5 but less than 1 corresponding to 
anomalous transport which occurred as a result of a coupling of both Fickian diffusion 
and polymer relaxation.  Also termed non-Fickian release this type of drug release 
occurs due to a combination of macromolecular relaxations and Fickian diffusion.45  
An exponent value of 1 represents time independent zero order release, whereas a 
value equal to 0.5 represents purely diffusion controlled release.46  More commonly, 
as in this case, both erosion and diffusion contribute to the eventual release of drug 
from the delivery vehicle via anomalous transport.47   
The mechanism of drug release is highly dependent on the solubility of the 
drug and the swelling and erosion properties of the polymer matrix.  Highly soluble 
drugs, for example vancomycin, will diffuse easily through the hydrogel layer with 
drugs with poor aqueous solubility released via a slower erosion and anomalous 
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diffusion mechanism resulting from the relaxation of polymer chains.48  The 
importance of solubility is demonstrated by comparison of the exponent values 
obtained for immersion loaded drugs.  Vancomycin possessed the lowest value of n 
all compounds tested (20µg/mL loading, n = 0.7251 ± 0.01).  This figure is the closest 
to the true diffusion value of n = 0.5 of all the immersion loaded drugs tested due to 
the high solubility of vancomycin in comparison to the peptides tested.  The aqueous 
solubility of vancomycin (152mg/mL) in PBS is almost three times greater than H-
Orn-Orn-Trp-Trp-NH2 (65mg/mL), the most soluble peptide tested.  The majority of 
release exponent values for immersion loaded drugs, as displayed in Table 4, were 
closer to 1, indicating that release is more dependent on erosion and/or relaxation of 
the polymeric chains.  It is possible that immersion in concentrated solutions (as low 
as 5mg/mL) of cationic antimicrobial peptides may have compromised the polymer 
structure.  These peptides have demonstrated detergent like properties against both 
prokaryotic and eukaryotic membranes.20  The use of similar cationic disinfectants 
such as benzalkonium chloride has been shown to have a deleterious effect on 
poly(HEMA) contact lenses.40  It is possible that similar erosion by cationic peptides 
may influence release to a higher degree than diffusion.  For matrix loaded hydrogels, 
as outlined in Table 3, the highest value for n was 0.6230±0.03 for poly(HEMA) 
containing 0.5% C12-Orn-Orn-Trp-Trp-NH2.  Thus, although release is defined as 
anomalous transport, release exponent values are closer to that of diffusional release 
(n = 1). 
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3.2  Anti-adherent Properties of Matrix and Immersion Loaded Poly(HEMA) 
Hydrogels against Staphylococcus epidermidis ATCC 35984  
The anti-adherent properties of matrix and immersion loaded H-Orn-Orn-Trp-Trp-
NH2, C12-Orn-Orn-Trp-Trp-NH2, maximin-4 and vancomycin containing poly(HEMA) 
hydrogels were tested against the Gram-positive bacterium Staphylococcus 
epidermidis ATCC 35984.  This strongly adherent, slime-producing, pathogenic strain 
of Staphylococcus epidermidis utilises the icaADBC operon to produce 
polysaccharide intercellular adhesin49 and has commonly been used to evaluate the 
anti-biofilm activity of medical device and compounds in the literature.21, 50, 51  
Results are displayed in Figures 3-8 as mean percentage adherence in proportion to 
positive poly(HEMA) controls as utilised in many studies.24  Analysis of results show 
a correlation between both the amount of compound released; the relative MICs, 
MBCs and MBECs of each compound against Staphylococcus epidermidis ATCC 
35984 as reported previously by our group;20 the mean percentage adherence and the 
time point analysed.  All matrix and immersion loaded vancomycin, maximin-4, H-
Orn-Orn-Trp-Trp-NH2 and C12-Orn-Orn-Trp-Trp-NH2 display highly significant 
reduction in adherence (p<0.001) compared to positive controls at the same time 
points.  
For matrix loaded poly(HEMA) hydrogels, all 5% peptide containing samples 
showed reduced adherence at 1, 4 and 24 hours when compared with 1% and 0.5% 
due to an increased concentration of antimicrobial peptide released at each time point.  
At 1 hour both 5% matrix loaded C12-Orn-Orn-Trp-Trp-NH2 and maximin-4 had a 
mean percentage adherence of 0% relative to the positive control.  This corresponds 
to a mean release of 544µg and 549µg for C12-Orn-Orn-Trp-Trp-NH2 and maximin-4 
respectively (Table 1).  As this release occurred in 10mLs of PBS, the concentration 
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of C12-Orn-Orn-Trp-Trp-NH2 was 54.4µg/mL and 54.9µg/mL for maximin-4 after 1 
hour.  This represents a concentration of more than 3.48 times the MBEC for C12-
Orn-Orn-Trp-Trp-NH2 (15.63µg/mL)20 and 1.75 times that for maximin-4 (MBEC: 
31.25µg/mL, previously unreported).  Therefore non-adherence of microorganism to 
poly(HEMA) samples may be due to rapid eradication of both planktonic and biofilm 
forms of microorganisms by both C12-Orn-Orn-Trp-Trp-NH2 and maximin-4, in the 
area surrounding the hydrogel, at the microbicidal concentrations demonstrated.  
Results at 4 and 24 hours correspond to reduced adhesion relative to positive control 
due to increased concentration and microbicidal action of the matrix loaded peptide 
antimicrobials.  At 24 hours 0.5, 1% and 5% C12-Orn-Orn-Trp-Trp-NH2 demonstrated 
0% mean percentage adherence corresponding to a cumulative release of 454 
(45.4µg/mL), 554 (55.4µg/mL) and 1650µg (165µg/mL) with concentrations again 
above MBEC for C12-Orn-Orn-Trp-Trp-NH2 against Staphylococcus epidermidis 
ATCC 35984.  1% (concentration of peptide present: 37.8µg/mL) and 5% 
(concentration of peptide present: 192µg/mL) maximin-4 (MBEC: 31.25µg/mL) also 
demonstrated 0% adherence for similar reasons.  Although the matrix loaded 
tetrapeptide H-Orn-Orn-Trp-Trp-NH2 displayed reduced adherence relative to positive 
poly(HEMA) control, 0% adherence and total non-adherence of Staphylococcus 
epidermidis ATCC 35984 was not achieved.  At time 24 hours and a matrix loaded 
concentration of 5%, H-Orn-Orn-Trp-Trp-NH2 only reduced adherence to its lowest 
value of 36.5% ± 5.10%.  This is due most likely to the sub-MBEC value 
(95.9µg/mL, MBEC: 500µg/mL) of H-Orn-Orn-Trp-Trp-NH2 released from a 5% 
poly(HEMA) hydrogel after 24 hours.  
Matrix loaded maximin-4 and C12-Orn-Orn-Trp-Trp-NH2 hydrogels were 
shown to have statistically significant reduction (p < 0.001) in adherence compared to 
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the same concentrations of vancomycin after 1 hour.  This can be attributed to rapid 
membrane targeting by these antimicrobial peptides.  Vancomycin’s mechanism of 
action is mainly focused on disruption of cell wall synthesis and possibly also through 
inhibition of bacterial RNA synthesis.52  This targeting of metabolic pathways leads to 
a reduction in initial kill of Staphylococcus epidermidis ATCC 35984 and an increase 
in adherence relative to both maximin-4 and C12-Orn-Orn-Trp-Trp-NH2.  Similar 
results are obtained for immersion loaded hydrogels of vancomycin.  Despite a 
cumulative mass of 2900µg released from 20mg/mL immersion loaded vancomycin 
after 1 hour, adherence is still significantly higher (p < 0.001) than that of the three 
antimicrobial peptides.  No significant difference (p > 0.05) between matrix and 
immersion loaded vancomycin, maximin-4 and C12-Orn-Orn-Trp-Trp-NH2 adherence 
are observed at similar concentrations after 4 hours.  After 4 hours vancomycin 
demonstrates effective cidal action via its targeting of metabolic pathways.  Similar 
results are obtained for immersion loaded hydrogels of vancomycin.   
Immersion loaded H-Orn-Orn-Trp-Trp-NH2, C12-Orn-Orn-Trp-Trp-NH2, 
maximin-4 and vancomycin show a similar trend of adherence related to 
concentration of compound released.  All concentrations of C12-Orn-Orn-Trp-Trp-
NH2 and maximin-4 demonstrate 0% adherence after 1 and 4 hours exposure to 
Staphylococcus epidermidis ATCC 35984.  These results occur due to the relatively 
rapid release of high concentrations of antimicrobial peptide within 4 hours.  For 
example, 5mg/mL immersion loaded poly(HEMA) released a cumulative 725µg 
(concentration: 72.5µg/mL) of C12-Orn-Orn-Trp-Trp-NH2 after 1 hour, 4.64 times that 
of the MBEC (15.63µg/mL) against Staphylococcus epidermidis ATCC 35984.  
Vancomycin shows a maximum reduction in adherence to 0 ± 0% for 20mg/mL 
immersion loaded and 3.55% ± 1.27% for 5% matrix loaded poly(HEMA) samples 
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after 24 hours.  Complete bactericidal non-adherence was not achieved within 4 
hours, similar to results obtained by Kodjikian et al,53 due to the bactericidal 
mechanism of action of vancomycin focusing on time dependant metabolic/synthesis 
pathways.  Results published by Ceri et al,21 show vancomycin to have an MBEC 
value above tested concentration limits (>1000µg/mL) therefore there is an increasing 
need for alternative antimicrobials to combat the threat posed by biofilm related 
resistance.  Initial comparison of adherence results for both matrix and immersion 
loaded hydrogels show immersion loaded samples to have a more favourable lower 
adherence profile for all peptides over 1, 4 and 24 hours.  A slower sustained release 
of peptide from matrix loaded samples resulted in longer times to reach MBEC and 
microbicidal concentrations, resulting in increased adherence of Staphylococcus 
epidermidis ATCC 35984.   
 
4  Conclusions 
In summary, the use of antimicrobial peptides and in particular C12-Orn-Orn-
Trp-Trp-NH2 described here as antimicrobial agents for the prevention of device 
associated infections by Staphylococcus epidermidis show significant promise.  
Staphylococcus epidermidis is a major causative organism in the infection of 
peritoneal dialysis and intravascular catheters; prosthetic valve endocarditis; 
prosthetic implants and contact lenses.54  The significance of these results are that 
improved clinical outcomes may be provided by the potential use of antimicrobial 
peptides either alone or in combination with standard therapeutic regimens.   
The rapid cidal action of C12-Orn-Orn-Trp-Trp-NH2 and maximin-4 via their action 
on bacterial membranes demonstrates that these compounds could have potential in 
the prevention and treatment of medical device related infections.  This approach may 
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lead to the utilisation of potent antimicrobial peptides which, due to poor 
pharmacological profile and bioavailability issues, have been (up until now) regarded 
as of little clinical value.  The direct incorporation of antimicrobial peptides into 
hydrogel matrices requires still more refinement to match release profile with device 
residence time in the body, however, delivery in this format facilitates a localised 
antimicrobial effect whilst avoiding the potential side effects of such agents in vivo.  
The demand for novel antimicrobials, which are active against these biofilm forming 
resistant pathogens, has become one of the greatest challenges in the management of 
infectious diseases such as medical device related infection.  Efforts have intensified 
to discover novel alternatives but at a decreasing rate compared with the emergence of 
resistant strains.  Cationic antimicrobials with their multiple membranous, metabolic 
and cellular microbial targets reduce the ability of these pathogens to develop 
resistance.  With thousands of naturally sourced antimicrobial peptides and millions 
of potential synthetic possibilities antimicrobial have the potential to solve the 
impending antimicrobial crisis.55 
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Legends for Figures 
FIGURE 1. The cumulative percentage drug release of C12-Orn-Orn-Trp-Trp-NH2 
released (µg) from a 0.5%, 1% and 5% matrix loaded poly(HEMA) hydrogel into 
37ºC 10mLs PBS, pH 7.4, over a period of 2 weeks.  Results are displayed as the 
mean of five replicates.  Concentrations obtained via UV-visible spectroscopy from a 
fresh standard calibration curve (five replicates) of equation y = 0.0075x (R2=0.999, 
280nm) 
 
FIGURE 2. The cumulative percentage drug release of C12-Orn-Orn-Trp-Trp-NH2 
released (µg) from a 20, 10 and 5mg/mL immersion loaded poly(HEMA) hydrogel 
into 37ºC 10mLs PBS, pH 7.4, over a period of 78 hours.  Results are displayed as the 
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mean of five replicates.  Concentrations obtained via UV-visible spectroscopy from a 
fresh standard calibration curve (five replicates) of equation y = 0.0075x (R2=0.999, 
280nm) 
 
FIGURE 3. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 0.5%, 1% and 5% vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-NH2 
and C12-Orn-Orn-Trp-Trp-NH2 matrix loaded, 1% EGDMA crosslinked, 
poly(HEMA) hydrogels relative to positive control (no drug) after 1 hour.  Results are 
displayed as the mean of five samples 
 
FIGURE 4. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 0.5%, 1% and 5% vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-NH2 
and C12-Orn-Orn-Trp-Trp-NH2 matrix loaded, 1% EGDMA crosslinked, 
poly(HEMA) hydrogels relative to positive control (no drug) after 4 hours.  Results 
are displayed as the mean of five samples 
 
FIGURE 5. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 0.5%, 1% and 5% vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-NH2 
and C12-Orn-Orn-Trp-Trp-NH2 matrix loaded, 1% EGDMA crosslinked, 
poly(HEMA) hydrogels relative to positive control (no drug) after 24 hours.  Results 
are displayed as the mean of five samples 
 
FIGURE 6. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 5, 10 and 20mg/mL vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-
NH2 and C12-Orn-Orn-Trp-Trp-NH2 immersion loaded, 1% EGDMA crosslinked, 
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poly(HEMA) hydrogels relative to positive control (no drug) after 1 hour.  Results are 
displayed as the mean of five samples 
 
FIGURE 7. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 5, 10 and 20mg/mL vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-
NH2 and C12-Orn-Orn-Trp-Trp-NH2 immersion loaded, 1% EGDMA crosslinked, 
poly(HEMA) hydrogels relative to positive control (no drug) after 4 hours.  Results 
are displayed as the mean of five samples 
 
FIGURE 8. The mean percentage adherence (%) of Staphylococcus epidermidis 
ATCC 35984 to 5, 10 and 20mg/mL vancomycin, maximin-4, H-Orn-Orn-Trp-Trp-
NH2 and C12-Orn-Orn-Trp-Trp-NH2 immersion loaded, 1% EGDMA crosslinked, 
poly(HEMA) hydrogels relative to positive control (no drug) after 24 hours.  Results 
are displayed as the mean of five samples 
 
Caption for all Figures 
Statistical significance (one way ANOVA and a Tukey-Kramer multiple comparisons 
test) of adherence to matrix loaded antimicrobial peptide hydrogels relative to the 
same % loading and time point of standardised vancomycin control are indicated as 
follows: 
p<0.001 *** 
p<0.01 ** 
p< 0.05 * 
ns: no significant difference 
Matrix (5,1 and 0.5%) and immersion (20, 10 and 5mg/mL) loaded vancomycin, 
maximin-4, H-Orn-Orn-Trp-Trp-NH2 and C12-Orn-Orn-Trp-Trp-NH2 5,1 and 0.5% 
display high significant differences (p<0.001) compared to positive controls at the 
same time points via a one way ANOVA and a Tukey-Kramer multiple comparisons 
test	
